Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Paraneoplastic syndromes (2)]

A Lortholary1, M Cossee, E Gamelin

  • 1Centre Paul-Papin, Angers, France.

Bulletin Du Cancer
|April 1, 1993
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Limb Girdle Muscular Dystrophy Associated With TRIM32 Variants: A National Cohort Study.

Muscle & nerve·2026
Same author

Kinetics and determinants of ESR1 mutation detection in metastatic breast cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2025
Same author

ENGOT-en11/GOG-3053/KEYNOTE-B21: a randomised, double-blind, phase III study of pembrolizumab or placebo plus adjuvant chemotherapy with or without radiotherapy in patients with newly diagnosed, high-risk endometrial cancer.

Annals of oncology : official journal of the European Society for Medical Oncology·2024
Same author

Olaparib plus bevacizumab first-line maintenance in ovarian cancer: final overall survival results from the PAOLA-1/ENGOT-ov25 trial.

Annals of oncology : official journal of the European Society for Medical Oncology·2023
Same author

Noninvasive prenatal diagnosis of genetic diseases induced by triplet repeat expansion by linked read haplotyping and Bayesian approach.

Scientific reports·2022
Same author

Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network.

Gynecologic oncology·2020
Same journal

[ONCONNECTE À L'EMPLOI, feedback after three years of a program to prepare for returning to work after cancer in Franche-Comté].

Bulletin du cancer·2026
Same journal

[Off-label use of venetoclax in myeloma].

Bulletin du cancer·2026
Same journal

[Cemiplimab - Adjuvant treatment for the cutaneous squamous cell carcinomas with high risk of relapse, operated and treated by radiotherapy].

Bulletin du cancer·2026
Same journal

Real-world outcomes and management of endometrial cancer in France from 2016 to 2021 (MOONBEAM study).

Bulletin du cancer·2026
Same journal

[Cardiotoxicity in children and adolescents with acute leukemia: Recommendations from the Leukemia Committee of the French Society of Childhood Cancer (SFCE)].

Bulletin du cancer·2026
Same journal

[Reirradiation: A new therapeutic paradigm in oncology].

Bulletin du cancer·2026
See all related articles

Paraneoplastic syndromes, though uncommon, are often underestimated in cancer patients. A proposed diagnosis score aims to simplify identifying these crucial malignancy indicators.

Area of Science:

  • Oncology
  • Neurology
  • Endocrinology

Context:

  • Paraneoplastic syndromes are a diverse group of disorders occurring in cancer patients.
  • Their true incidence is likely underestimated in clinical practice.
  • These syndromes represent a significant challenge in cancer diagnosis and management.

Purpose:

  • To describe the clinical features and significance of paraneoplastic syndromes.
  • To highlight their role as potential early indicators of malignancy.
  • To introduce a diagnostic score for simplifying the identification of these syndromes.

Summary:

  • Paraneoplastic syndromes, while not rare, affect a minority of cancer patients and are often underdiagnosed.
  • They possess significant clinical utility, serving as early warning signs for underlying cancers and functioning as tumor markers.

Related Experiment Videos

  • The diagnosis can be challenging, necessitating the proposal of a 'diagnosis score' to facilitate easier identification.

    • Impact:

    • Improved early detection of malignancies through recognition of paraneoplastic syndromes.
    • Enhanced diagnostic accuracy for challenging cases.
    • Potential for improved patient outcomes through timely cancer diagnosis and treatment.